Clinical Trial Update: Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating Aldesleukin (IL-2) after Zanolimumab in metastatic melanoma and metastatic renal cell carcinoma was terminated, with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• Aldesleukin (interleukin-2)
• Zanolimumab (zanolimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Melanoma, Metastatic Renal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2012-12-11